Treatment of Venous Thromboembolism with Low-Molecular-Weight Heparin. Hull RD, Pineo GF. J Thromb Thrombolysis. 1995;1(3):279-284. doi: 10.1007/BF01060737. PMID: 10608005
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Kahale LA, Matar CF, Hakoum MB, Tsolakian IG, Yosuico VE, Terrenato I, Sperati F, Barba M, Schünemann H, Akl EA. Cochrane Database Syst Rev. 2021 Dec 08;12:CD006649. doi: 10.1002/14651858.CD006649.pub8. PMID: 34878173
New Therapeutic Opportunities for Heparins: What Does Low Molecular Weight Heparin Offer?. Turpie AG. J Thromb Thrombolysis. 1996;3(2):145-149. doi: 10.1007/BF00132407. PMID: 10602555
Low-Molecular-Weight Heparin Should Replace Unfractionated Heparin for Treatment of Venous Thrombosis and Unstable Angina. Hirsh J. J Thromb Thrombolysis. 1997;4(3):349-351. doi: 10.1023/a:1008893231863. PMID: 10639640
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Kahale LA, Matar CF, Hakoum MB, Tsolakian IG, Yosuico VE, Terrenato I, Sperati F, Barba M, Schünemann H, Akl EA. Cochrane Database Syst Rev. 2021 Dec 08;12:CD006649. doi: 10.1002/14651858.CD006649.pub8. PMID: 34878173
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Kahale LA, Matar CF, Hakoum MB, Tsolakian IG, Yosuico VE, Terrenato I, Sperati F, Barba M, Schünemann H, Akl EA. Cochrane Database Syst Rev. 2021 Dec 08;12:CD006649. doi: 10.1002/14651858.CD006649.pub8. PMID: 34878173
Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins. Becker RC, Spencer F. J Thromb Thrombolysis. 1997;4(2):197-205. doi: 10.1023/a:1008870228789. PMID: 10639262
Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes. Chao BH, Lepeak L, Leal T, Robins HI. Thrombosis. 2011;2011:530183. doi: 10.1155/2011/530183. Epub 2011 Apr 12. PMID: 22084664